Literature DB >> 9690766

Was tumour necrosis factor-alpha responsible for the fetal malformations associated with thalidomide in the early 1960s?

J M Argilés1, N Carbó, F J López-Soriano.   

Abstract

Prescription of thalidomide as a sedative to pregnant women in the early 1960s resulted in a dramatic number of fetal malformations that affected over ten thousand babies. Although tumour necrosis factor-alpha (TNF-alpha) is basically a cytotoxic molecule produced by macrophages when activated by invasive stimuli (such as bacterial endotoxin or tumour growth), it could have an important role in pregnancy, especially in early embryonic development. On these lines, both in human subjects and experimental animals, the cytokine is expressed and synthesized in endometrium, placenta and fetus. Evidence is presented here suggesting that the embryonic action of thalidomide was mediated by TNF-alpha, since the drug is a powerful inhibitor of the synthesis of this cytokine.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9690766     DOI: 10.1016/s0306-9877(98)90003-2

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  4 in total

1.  Chemotherapy and other systemic therapies for hepatocellular carcinoma and liver metastases.

Authors:  Kevin S Brown
Journal:  Semin Intervent Radiol       Date:  2006-03       Impact factor: 1.513

2.  Phase II trial and pharmacokinetic study of thalidomide in patients with metastatic colorectal cancer.

Authors:  Lissandra Dal Lago; Marc F Richter; Anna I Cancela; Sabrina A Fernandes; Keylla T Jung; Ana C Rodrigues; Teresa Dalla Costa; Luciane P Di Leone; Gilberto Schwartsmann
Journal:  Invest New Drugs       Date:  2003-08       Impact factor: 3.850

Review 3.  Lenalidomide in myelodysplastic syndrome and multiple myeloma.

Authors:  Sachin R Shah; Thu M Tran
Journal:  Drugs       Date:  2007       Impact factor: 9.546

4.  Angiopoietin-2 primes infection-induced preterm delivery.

Authors:  Electra N Polyzou; Nikolaos E Evangelinakis; Aikaterini Pistiki; Antigone Kotsaki; Charalampos S Siristatidis; Charalambos G Chrelias; Emmanuel Salamalekis; Demetrios P Kassanos; Evangelos J Giamarellos-Bourboulis
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.